Diosmin and hesperidin are citrus-derived bioflavonoids most often studied together as micronized purified flavonoid fraction (MPFF), a 9:1 diosmin-to-hesperidin format with an unusually deep human clinical record. In Lympha, this pair anchors the venous-comfort and microcirculatory side of the formula — systems that influence how fluid is carried, filtered, and managed in tissue.
What the human research shows
Objective fluid-balance measures
A 2023 systematic review and meta-analysis of prospective MPFF studies reported mean circumference reductions of about 6.0 mm (ankle) and 5.7 mm (calf) at ~2 months, sustained at about 7.0 mm and 6.7 mm by ≥6 months. These are objective circumference measures, not symptom-only outcomes.[1]
Symptoms and quality of life
Controlled trials using the Daflon 500 mg format report improvements versus placebo in heaviness, discomfort, cramps, and “feeling of swelling,” with quality-of-life scores improving alongside.[2]
Large-scale, real-world signal
In RELIEF (n ≈ 5,052; 6 months; no placebo control), MPFF use tracked with progressive symptom and quality-of-life improvement (CIVIQ), with edema measured by leg circumference. Although observational, it adds time-course and scale.[3]
Depth of the clinical record
The diosmin–hesperidin evidence base spans a broad range of venous-health research contexts — a depth few ingredients in this category can match.[4]
Much of the pooled circumference literature uses 1000 mg/day MPFF and was conducted in chronic venous disease populations. Lympha uses the classic 450 mg diosmin + 50 mg hesperidin ratio as part of a broader daily fluid-balance formula.
- Dose in Lympha
- 450 mg + 50 mg / day
- Studied format
- MPFF (9:1 with hesperidin)
- Measured endpoints
- Ankle/calf circumference, symptom scores, QoL, severity indices
- Role in the system
- Venous comfort · microvascular function · fluid-balance context